Pegylated interferon alfa-2a versus emtricitabine/tenofovir +/- pegylated interferon alfa-2a for the treatment of chronic HBe-Ag [hepatitis B e antigen]-positive hepatitis B infection in HIV-coinfected patients - the PEGPLUS trial

Trial Profile

Pegylated interferon alfa-2a versus emtricitabine/tenofovir +/- pegylated interferon alfa-2a for the treatment of chronic HBe-Ag [hepatitis B e antigen]-positive hepatitis B infection in HIV-coinfected patients - the PEGPLUS trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2009

At a glance

  • Drugs Emtricitabine; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
  • Indications Hepatitis B; HIV infections
  • Focus Therapeutic Use
  • Acronyms PEGPLUS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Feb 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top